


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231 on March 29, 2002.



1633

#5  
ML

INFORMATION DISCLOSURE STATEMENT  
Examining Group 1633  
Patent Application  
Docket No. UF-293  
Serial No. 10/036,988

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (not yet assigned)  
Art Unit : 1633  
Applicant : Roger L. Papke  
Serial No. : 10/036,988  
Filed : December 31, 2001  
For : Compositions and Methods for Treatment of Neurological Disorders

RECEIVED

APR 05 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

Applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Glenn P. Ladwig

Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

GPL/mv

Attachments: Form PTO-1449; copies of references cited therein.